CREATIVE MEDICAL TECHNOLOGY

CELZ stock represents shares of Creative Medical Technology Holdings, a biotechnology company. The ticker trades on the Nasdaq Capital Market under the symbol CELZ. The company focuses on developing cell-based therapies for conditions such as erectile dysfunction, female infertility, and immune disorders. As a small-cap biotech, its stock reflects the market's view of its pipeline progress and commercial prospects.

CELZ operates in the biotechnology and regenerative medicine sector. Its work centers on cellular therapies, including stem cell research and immunology-based treatments. This places CELZ within the broader healthcare industry, where clinical trial outcomes and regulatory decisions often drive stock sentiment. Understanding the biotech industry helps contextualize CELZ's business model and risk profile.

Recent performance for CELZ depends on the latest market data, which changes frequently. To see how the stock has moved over the past days, weeks, or months, check the price chart and performance figures displayed on this CELZ page. Those sections show up-to-date returns and trading ranges rather than static historical values.

For a clinical-stage biotech like CELZ, traditional valuation metrics may be less meaningful because earnings are often negative or minimal. Instead, consider cash position, pipeline progress, and potential market opportunity. Compare CELZ's market capitalization and price-to-book ratio with peers, but avoid relying on a single metric. The valuation section on this page provides relevant current figures for context.

Fractional shares of CELZ may be available through certain brokerages that offer this feature. It allows investors to purchase less than one full share, making it easier to invest a specific dollar amount. Availability depends on the platform, so check with your brokerage to see if fractional trading is supported for CELZ.

CELZ does not currently pay dividends. As a clinical-stage biotechnology company, it likely reinvests any available capital into research and development. For the most current dividend information, including any changes to this policy, please refer to the dividend section on this CELZ page.